Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study
Clinical Lymphoma Myeloma and Leukemia · 2023
DOI: 10.1016/j.clml.2023.05.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Tony Zibo Zhuang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emory University School of Medicine, Atlanta, GA. Electronic address: ztzhuan@emory.edu. Hauptthemen laut MEDLINE: Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Conquer Cancer Foundation, Lymphoma Research Foundation.
Abstract (Originalsprache)
INTRODUCTION: Visceral involvement of cutaneous T-cell lymphoma (vCTCL) is a rare but poorly studied complication of CTCL. We aimed to assess clinical characteristics, treatment, and outcomes, associated with vCTCL at our institution. METHODS: We conducted a retrospective review of patients with vCTCL among patients with a confirmed histopathologic diagnosis of CTCL seen at the Winship Cancer Institute in Emory University. vCTCL was defined as a highest TNMB stage of 4B with extracutaneous metastatic disease (M1) pathologically confirmed or strongly clinically suspected based on imaging, symptoms, and the clinical judgment of the treating physician. Patients were selected from our CTCL database containing 656 patients from 1990 to 2022. Clinical characteristics were characterized. Clinical outcomes were measured as overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier curve and univariable Cox regression analysis. RESULTS: Twenty-six of 656 patients with vCTCL were identified. 42.3% of patients were black. Twenty-two patients were diagnosed with MF/SS and 4 had other CTCL subtypes including pcALCL, Gamma-Delta, and Cytotoxic T-Cell Lymphoma. The median PFS and OS were 7.3 months (3.8, 11) and 12.1 months (9.9, 18.2), respectively. Median time to metastasis from initial diagnosis was 12.1 months. The most common M1 sites were liver (19.2%) and lung (42.3%). M1 sites outside of liver or lung were associated with inferior OS (HR 8.9, 95%CI: 2.7-29.5, P-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Emory University School of Medicine, Atlanta, GA. Electronic address: ztzhuan@emory.edu.
- Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA.
- Department of Medicine, Emory University School of Medicine, Atlanta, GA.
- Department of Dermatology, Emory University School of Medicine, Atlanta, GA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
Förderung
- NCI NIH HHS
- Conquer Cancer Foundation
- Lymphoma Research Foundation
- National Institutes of Health
- Winship Cancer Institute
- Kyowa Kirin Pharmaceutical Development
- National Cancer Institute
Zitieren
APA
Zhuang, T. Z., McCook-Veal, A., Switchenko, J., Niyogusaba, T., Tarabadkar, E. S., Baird, K., O'Leary, C., Paulino, D., Lechowicz, M. J., & Allen, P. B. (2023). Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.05.001
Vancouver
Zhuang TZ, McCook-Veal A, Switchenko J, Niyogusaba T, Tarabadkar ES, Baird K, et al. Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.05.001
BibTeX
@article{Zhuang2023,
author = {Zhuang, Tony Zibo and McCook-Veal, Ashley and Switchenko, Jeffrey and Niyogusaba, Tim and Tarabadkar, Erica S and Baird, Katelin and O'Leary, Colin and Paulino, Darina and Lechowicz, Mary Jo and Allen, Pamela B},
title = {Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
doi = {10.1016/j.clml.2023.05.001}
}
EUVIMED